Equipping NK Cells with CARs

Cancer Discov. 2017 Oct;7(10):OF2. doi: 10.1158/2159-8290.CD-NB2017-124. Epub 2017 Sep 6.

Abstract

Adding a chimeric antigen receptor (CAR) to natural killer (NK) cells is garnering interest as a therapeutic strategy because this immune cell type doesn't cause graft-versus-host disease, making its widespread, off-the-shelf use feasible. Based on promising preclinical data, a phase I/II trial of one such CAR NK-cell therapy is under way, targeting CD19 in hematologic malignancies.

Publication types

  • Comment

MeSH terms

  • Fetal Blood
  • Immunotherapy, Adoptive*
  • Interleukin-15
  • Killer Cells, Natural*

Substances

  • Interleukin-15